Mirum Pharmaceuticals Stock Surges 12% on Trial Results

Mirum Pharmaceuticals shares jumped about 12% after its VISTAS Phase 2b trial of volixibat met primary endpoint in PSC patients.
The study showed a 2.72‑point baseline itch reduction and 1.64‑point placebo‑adjusted improvement (p=0.0019) with 55.6% achieving ≥2‑point drop.
Volixibat also reduced serum bile acids by 35.8 points versus placebo (p=0.0324) and had 9.1% discontinuation rate versus 2.5% placebo.
Mirum plans a pre‑NDA FDA meeting summer 2026, NDA filing H2 2026, and will present full data May 30; analyst maintains $112 target.